{
    "clinical_study": {
        "@rank": "20121", 
        "arm_group": {
            "arm_group_label": "Ranibizumab", 
            "arm_group_type": "Experimental", 
            "description": "monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections)."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety of intravitreal ranibizumab repeated injections in patients with\n      diabetic macular edema regarding maintenance of retinal ganglion cell function."
        }, 
        "brief_title": "Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Synovial Cyst", 
                "Ganglion Cysts", 
                "Macular Edema"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Ranibizumab can be a safe treatment for diabetic macular edema regarding maintenance of\n           retinal ganglion cell function after repeated intravitreal injections.\n\n        -  To evaluate the safety of intravitreal ranibizumab repeated injections in patients with\n           diabetic macular edema regarding maintenance of retinal ganglion cell function.\n\n        -  The primary endpoint for the study will be the changes in full-field and focal macular\n           photopic negative response (PhRN) amplitude (in \u00b5V) over time, from baseline to month\n           12."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients, older than 18 years, who have signed an informed consent.\n\n          -  Patients with Type 1 or Type 2 diabetes mellitus and prior diagnosis of diabetic\n             macular edema (DME), who had not undergone any previous treatment, either\n             pharmacological or laser photocoagulation.\n\n          -  Patients with visual impairment due to DME whom, in the opinion of the investigator,\n             would benefit from treating with IVR.\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to ranibizumab or any of its components.\n\n          -  Previous participation in any clinical studies of investigational drugs within 1\n             month\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant, including women whose career, lifestyle, or sexual orientation\n             precludes intercourse with a male partner and women whose partners have been\n             sterilized by vasectomy or other means, UNLESS they are using two birth control\n             methods. The two methods can be a double barrier method or a barrier method plus a\n             hormonal method. Adequate barrier methods of contraception include: diaphragm, condom\n             (by the partner), intrauterine device (copper or hormonal), sponge or spermicide.\n             Hormonal contraceptives include any marketed contraceptive agent that includes an\n             estrogen and/or a progestational agent.\n\n          -  Pregnant or nursing (lactating) women.\n\n          -  Inability to comply with study or follow-up procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055911", 
            "org_study_id": "Retinal Ganglion Cell_DME"
        }, 
        "intervention": {
            "arm_group_label": "Ranibizumab", 
            "description": "monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).", 
            "intervention_name": "Ranibizumab", 
            "intervention_type": "Drug", 
            "other_name": "Lucentis"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "diabetic macular edema", 
            "intravitreal ranibizumab", 
            "f retinal ganglion cell"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "contact": {
                "email": "crissmucci@gmail.com", 
                "last_name": "Cristina Muccioli, MD", 
                "phone": "551155726443"
            }, 
            "contact_backup": {
                "email": "luci.silva@unifesp.br", 
                "last_name": "Luci Silva, MBA", 
                "phone": "551155726443"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "04023-062"
                }, 
                "name": "Dept of Ophthalmology - UNIFESP/Hospital S\u00e3o Paulo"
            }, 
            "investigator": [
                {
                    "last_name": "Eduardo Novais, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Emmerson Badaro, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ricardo Japiassu, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Retinal Ganglion Cell Function After Repeated Intravitreous Ranibizumab in Diabetic Macular Edema", 
        "other_outcome": {
            "description": "To assess adverse events during the twelve months of the study.", 
            "measure": "assess adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "monthly, from Month 1 to Month 12"
        }, 
        "overall_contact": {
            "email": "eduardo@novais.md", 
            "last_name": "Eduardo Novais, MD", 
            "phone": "5521-98125-0506"
        }, 
        "overall_contact_backup": {
            "email": "luci.silva@unifesp.br", 
            "last_name": "Luci Silva, MBA", 
            "phone": "551155726443"
        }, 
        "overall_official": {
            "affiliation": "UNIFESP / HOSPITAL S\u00c3O PAULO", 
            "last_name": "Mauricio Maia, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The photopic negative response (PhNR) of the full-field cone electroretinograms (ERGs) is a functional indicator of retinal ganglion. The PhNR consists of a negative-going wave that follows the photopic cone b wave. The PhNR is selectively attenuated in patients with optic nerve disease and glaucoma, indicating that the PhNR can be an objective functional measure reflecting the sum of the total response of the retinal ganglion cells in the entire retina.", 
            "measure": "focal macular changes in full-field and photopic negative response (PhRN) amplitude (in \u00b5V)", 
            "safety_issue": "Yes", 
            "time_frame": "at Baseline and Months 3, 6, 9, 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055911"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Federal University of S\u00e3o Paulo", 
            "investigator_full_name": "Mauricio Maia", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The mean change in best corrected visual acuity (BCVA) from baseline to month 12", 
                "measure": "The mean change in BCVA", 
                "safety_issue": "Yes", 
                "time_frame": "monthly, from baseline to Month 12"
            }, 
            {
                "description": "To assess the mean change in central macular thickness (CMT), measured in spectral-domain optical coherence tomography (SD-OCT) from baseline to month 12", 
                "measure": "the mean change in central macular thickness (CMT)", 
                "safety_issue": "Yes", 
                "time_frame": "monthly, from baseline to Month 12"
            }
        ], 
        "source": "Federal University of S\u00e3o Paulo", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Federal University of S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}